Category Archives: Company News

Fairbanks Pharmaceuticals to compete in semifinals of Diabetes Innovation Challenge

Fairbanks Pharmaceuticals has been selected as a semi-finalist in the Diabetes Innovation Challenge sponsored by the T1D Exchange, the Massachusetts Medical Device Development Center (M2D2) at UMass, the Juvenile Diabetes Research Foundation (JDRF) and the American Diabetes Association (ADA).

The Challenge is a proposal- and presentation-based competition for small companies in the T1 and T2 space that are making real progress towards better outcomes for those diagnosed.  It offers the chance to win in-kind awards and receive early and later-stage validation of their ideas and products specific to Type 1 and Type 2 diabetes.

Read more about the Challenge, or come see  us at UMass Lowell on October 5th, 2016 at the pre-clinical “pitch-off.”

 

Fairbanks Pharmaceuticals awarded a Phase 1 SBIR grant for $192,101 by NIDDK/NIH

Dr. Alan Schneyer, CEO/CSO and Co-founder of Fairbanks Pharmaceuticals, is the Principal Investigator (PI) of an SBIR grant from The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH). The award begins immediately and funds our research that will identify a number of candidate compounds using our proprietary screening bioassay, comparing them for biochemical and biological properties, and testing the top candidates for biological activity in islet culture assays.

The award lasts for a one year period. It is anticipated that the successful completion of this Phase 1 award will lead to a larger Phase 2 award, which will allow testing the biological activity of lead compounds in animals. The goal of Fairbanks Pharmaceuticals, and this SBIR grant, is to develop compounds that lead to regeneration of insulin-producing beta cells to replace those lost to either type 1 or type 2 diabetes and thereby partially or completely eliminate diabetes in these patients. Stay tuned for progress reports….

Fairbanks Pharmaceuticals opens research laboratory

On November 25th, 2014, Fairbanks Pharmaceuticals opened its research laboratory in Springfield, Massachusetts.

Alan and Danielle 2
Technician Danielle Andrzejewski and CEO/CSO Alan Schneyer

The space is located at 3601 Main St within recently renovated open lab space that has a wealth of shared facilities available to Fairbanks scientists.

In our first two weeks we have been screening libraries to identify candidate compounds that we can then test for effectiveness in treating diabetes in animal models.  Its been a hectic start but now we are ready to focus on our research and hopefully make excellent progress.